The aim of this study is to investigate the effects of spironolactone on liver fibrosis progression and portal pressure gradient in patients with advanced chronic liver disease. Eligible cirrhosis patients were 2:1 randomized to either combination (carvedilol and spironolactone) or single (carvedilol) therapy group. Changes in virtual portal pressure gradient (vPPG) of portal trunk (calculated based on reconstructed 3D model and measured blood flow velocity), liver stiffness measurement (Fibroscan) and serum markers of liver fibrogenesis were documented at baseline and six months later.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
96
Patients are treated with carvedilol in combination with spironolactone.
Patients are treated with carvedilol only.
Shanghai Tongji Hospital, Tongji University
Shanghai, Shanghai Municipality, China
Virtual portal pressure gradient(vPPG)
Calculated based on reconstructed 3D portal trunk using anatomical information extracted from CT angiography and blood flow velocity measured by Doppler ultrasound
Time frame: 6 months
Liver stiffness measurement (LSM)
Detected using FibroScan
Time frame: 6 months
Occurence of portal hypertension-related complications
variceal bleeding, ascites, hepatic encephalopathy
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.